title: Dextran-conjugated vascular endothelial growth factor receptor antibody for in vivo melanoma xenografted mouse imaging.
abstract: Intact immunoglobulin G antibody has a relatively large molecule size of approximately 150 kDa that remains in the bloodstream for many weeks, which is a considerable disadvantage when it is used to carry radioactive materials for imaging. To lower background activity and increase the contrast of images, we investigated antivascular endothelial growth factor (VEGF) receptor 2 antibody (DC101) conjugated dextran for VEGF receptor 2 imaging in tumor xenografted mice. DTPA-conjugated aminodextran was synthesized, reacted with sulfo-LC-SPDP, and then reacted with DC101. The binding affinity of DTPA-dextran-DC101 to Flk-1 was measured. The gamma imaging and biodistributions of (99m)Tc-DTPA-dextran-DC101, (99m)Tc-DTPA-DC101, and (125)I-DC101 were studied in B16F10 melanoma xenografted mice. The dissociation values for DC101, DTPA-DC101, and DTPA-dextran-DC101 were 22.48, 3.05, and 14.74 pM, respectively. In gamma images, (99m)Tc-DTPA-dextran-DC101 showed weak liver uptake and rapid kidney elimination. In biodistribution results, the liver uptake of (99m)Tc-DTPA-dextran-DC101 was similar with that of (99m)Tc-DTPA-DC101 at each time point. However, the blood activity of (99m)Tc-DTPA-dextran-DC101 has shown significant differences, compared with (99m)Tc-DTPA-DC101 at all time points. The tumor accumulation of dextran-conjugated antibody was increased with time, whereas that of dextran nonconjugated antibody decreased. In particular, the pattern of tumor uptake of (99m)Tc-DTPA-dextran-DC101 was similar to that of (125)I-DC101, so this was thought to reflect the kinetics of DC101, unlike the nonconjugated form. The results of this study suggested that introduction of dextran moiety to make (99m)Tc-radiolabeled DC101 imaging agent could provide better images with the impaired background and the steady increasing binding to the receptor. However, further studies are necessary to improve clinical pharmacokinetics, such as enhancement of tumor uptake and impaired renal uptake.
authors.affiliation: Department of Nuclear Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Chonbuk, Republic of Korea.
authors.forename: Eun-Mi
authors.initials: EM
authors.lastname: Kim
authors.forename: Hwan-Jeong
authors.initials: HJ
authors.lastname: Jeong
authors.forename: Min-Hee
authors.initials: MH
authors.lastname: Jeong
authors.forename: Chang-Moon
authors.initials: CM
authors.lastname: Lee
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Cheong
authors.forename: Dong Wook
authors.initials: DW
authors.lastname: Kim
authors.forename: Seok Tae
authors.initials: ST
authors.lastname: Lim
authors.forename: Myung-Hee
authors.initials: MH
authors.lastname: Sohn
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000276:immunology / Q000493:pharmacokinetics; D003911:Dextrans / Q000737:chemistry* / Q000493:pharmacokinetics; D005260:Female; D008546:Melanoma, Experimental / Q000000981:diagnostic imaging* / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D004369:Pentetic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D011725:Pyridines / Q000737:chemistry; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000493:pharmacokinetics; D013386:Succinates / Q000737:chemistry; D013667:Technetium / Q000737:chemistry / Q000493:pharmacokinetics; D014018:Tissue Distribution; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000737:chemistry / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; C511761:DC101 monoclonal antibody; D003911:Dextrans; D011725:Pyridines; D019275:Radiopharmaceuticals; D013386:Succinates; C109849:sulfosuccinimidyl 6-(3'-(2-pyridyldithio)propionamido)hexanoate; D013667:Technetium; D004369:Pentetic Acid; D040301:Vascular Endothelial Growth Factor Receptor-2